

## Spectrophotometric determination of Montelukast Sodium in pure form and in its pharmaceutical formulations

Qabas Naji Rashid, Abdul-Hade Mohammed Nasief College of Education for pure science, Tikrit University, Tikrit, Iraq DOI: http://dx.doi.org/10.25130/tjops.14.1.02

## ARTICLE INFO.

#### **Article history:**

-Received: 22 / 7 / 2018 -Accepted: 19 / 11 / 2018 -Available online: 20 / 6 / 2019

Keywords: Montelukast Na, (KBr:KBrO3), Crystal Violet dye, spectrophotometric.

#### \*Corresponding author:

Email: <u>qabas.naji@tu.edu.iq</u>

Mobile : 009647716622336

**Contact To Journal** 



# 0. Abstract

 $\mathbf A$  simple, sensitive and rapid spectrophotometric method for determination of Montelukast Sodium (MON) in both pure form and pharmaceutical formulations was developed. This method was based on the oxidation of the studied drug in presence of acidic medium by a known excess of (Potassium bromide: Potassium bromate) (KBr:KBrO3) and subsequent determination of unreacted oxidant by reacting it with Crystal Violet (CV) dye [4 [bis [4 (dimethylamino) phenyl] methylidene] cyclohexa-2,5dien-1-ylidene]-dimethylazanium to produce blue product at λmax. 592 nm. The linearity range was found to be (5-50)µg/ml and molar absorptivity 1.5691×104 L/mol.cm, correlation coefficient 0.9993 and the limit of detection 0.209 µg/ml. This method was successfully applied for the determination of (MON) in tablet formulation.

التقدير الطيفى لمونتيليوكاست الصوديوم بشكله النقى وفى مستحضراته الصيدلانية

عبد الهادي محمد نصيف

قبس ناجي رشيد

الخلاصة

تم استحداث طريقة بسيطة وحساسة وسريعة لتقدير المركب الدوائي مونتيليوكاست الصوديوم بشكله النقي وفي مستحضراته الصيدلانية. اعتمدت الطريقة على أكسدة (MON) في الوسط الحامضي باستخدام عامل مؤكسد (بروميد البوتاسيوم: برومات البوتاسيوم) (KBr:KBrO3) يليها اضافة صبغة البنفسج البلوري

[4- bis [4-(dimethylamino) phenyl]methylidene]cyclohexa-2,5- (CV) Crystal Violet [4-(dimethylazanium) phenyl]methylidene]cyclohexa-2,5- (CV) Crystal Violet [4-(dimethylazanium) phenyl]methylidene]cyclohexa-2,5- (CV) Crystal Violet [4-(dimethylazanium) phenyl] dien-1-ylidene]- dimethylazanium; chloride [4-(dimethylazanium) phenyl] dien-1-ylidene]- dimethylazanium; chloride [4-(dimethylazanium) phenyl] dien-1-ylidene] dimethylazanium; chloride [4-(dimethylazanium) phenyl] dien-1-ylidene]- dimethylazanium; chloride [4-(dimethylazanium) phenyl] dien-1-ylidene]- dimethylazanium; chloride [4-(dimethylazanium) phenyl] dien-1-ylidene]- dimethylazanium; chloride [4-(dimethylazanium) phenyl] active [4-(dimethylazanium) phenyl] dien-1-ylidene] dimethylazanium; chloride [4-(dimethylazanium) phenyl] active [4-(dimethylazanium) phenyl] active [4-(dimethylazanium) phenyl] dimethylazanium; chloride [4-(dimethylazanium) phenyl] active [4-(dimethylazanium) phenyl] active [4-(dimethylazanium) phenyl] dimethylazanium; chloride [4-(dimethylazanium) phenyl] active [4-(dimethy

الكلمات المفتاحية: مونتيليوكاست الصوديوم، (بروميد البوتاسيوم:برومات البوتاسيوم)، صبغة البنفسج البلوري، مطيافية.

## Introduction

Montelukast Na (Fig.1), "used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies" [1,2] and used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma. Montelukast is also used prevent bronchospasm to (breathing difficulties) during exercise. It is also used to treat the symptoms of seasonal (occurs only at certain times of the year), and perennial (occurs all year round) allergic rhinitis (a condition associated with sneezing and stuffy, runny or itchy nose). It is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis<sup>[3]</sup>. Molar mass is 608.169 gm/mole, M.P. = 242.5 °C, is a hygroscopic, optically active, white to offwhite powder. Montelukast sodium is freely soluble in ethanol, methanol, and water and insoluble practically in acetonitrile. chemically known is sodium; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl) ethenyl] -3-[2-(2-hydroxypropan-2phenyl]

yl)phenyl]propyl]sulfanylmethyl]cyclopropy l]acetate <sup>[4]</sup>. Several methods have been proposed for determination of this drug, such as HPLC <sup>[5-7]</sup>, TLC <sup>[8,9]</sup>, HPTLC <sup>[10-12]</sup>, Voltammetry <sup>[13,14]</sup>, UV-Vis. Spectrophotometry <sup>[15-18]</sup>.



Fig. (1): Chemical Structures of Montelukast Na

The research aims to develop a simple, fast and economical spectrophotometric methods for determination of Montelukast Na by using dye with an oxidizing agent in the acid medium.

# Experimental Apparatus

T90 UV-VIS spectrophotometer double beam (PG Instruments Ltd, with 1 cm quartz cells), UV-VIS spectrophotometer single beam (Genesys UV 10), pH meter InoLab pH/INO735 (Jenway 3310), Balance Kern 770GS/GJ (Sartorius BL210S), Oven (Memmert, Schutzart DIN 40050-IP20).

## Materials

Monteiukast Na %99 (SDI Samarra-Iraq), KBr %99 (Merck), KBrO<sub>3</sub> %98 (Fluka), Crystal Violet (dye) %90 (Fluka), Ethanol %99.9 (Scharlau),  $H_2SO_4$  %98 (GCC), HCl %36 (Thomas baker), HNO<sub>3</sub> %70 (GCC), CH<sub>3</sub>COOH %98 (Scharlau), Lactose %99.5 (BDH), Mannitol %97 (Merck), Sodium benzoate %99 (BDH).

### Solutions

**Montelukast Na Stock solution (1000** µg/mL): An exactly (0.1000 gm) of (MON) "standard" were dissolved in (100 ml) ethanol.

(**KBr: KBrO<sub>3</sub>**): prepared by dissolving 1.0gm of potassium bromide, and 0.1000gm of potassium bromate in 100 ml distilled water <sup>[19]</sup>, then 2.5 ml of this mixure were diluted to 100 ml distilled water in a volumetric flask.

**Crystal Violet (CV) dye**: a concentration of  $7.7 \times 10^{-5}$  M was prepared by dissolving 0.0031 gm in 100 ml distilled water.

**Sulfuric acid solution**: an approximate concentration of 1.0 molar was prepared by diluting 5.4 ml of concentrated acid (18.4 M) to 100 ml distilled water.

**Hydrochloric acid solution:** an approximate concentration of 1.0 molar was prepared by diluting 8.6 ml of concentrated acid (11.64 M) to 100 ml distilled water.

Nitric acid solution: approximate concentration of 1.0 molar was prepared by diluting 6.3 ml of concentrated acid (15.78 M) to 100 ml distilled water.

Acetic acid solution: an approximate concentration of 1.0 molar was prepared by diluting 5.8 ml of concentrated acid (17.33 M) to 100 ml distilled water.

(Lactose, Mannitol and Sodium benzoate) solutions: a concentration of (1000 µg/mL)

was prepared by dissolving (0.1000) gm in 100 ml distilled water.

#### Procedures

After initial testing, optimal conditions were obtained, and the procedure involves transferring 0.5 ml of 500  $\mu$ g/ml (MON) to a 10 ml volumetric flask, then adding 0.75 ml of the oxidizing agent (KBr: KBrO3) by diluting (2.5 to 100 ml), followed by adding 0.5 ml of 1.0 M HCl acid. After 15 minutes, 1.0 ml of Crystal Violet dye were added, and after 5 minutes, the volume is completed with ethanol to 10 ml, because after five minutes the color of the blank disappears, the highest absorption of the resulting compound (blue color) absorbs at 592 nm.

Procedures for "stoichiometric ratio"

The reaction of equivalence between this drug and the reagent (dye), have been estimated by carrying out "molar ratio" and "continuous variation method". In these methods, "equimolar" solutions of (MON 0.5 ml) and "CV dye"  $(7.7 \times 10^{-5} \text{M})$  were used. In the first method varying aliquots of "CV dye" was added to constant aliquots of drug solution, final volumes (10ml) and the absorbance was measured at 592 nm, opposite the blank treated similarly. while in the latter method, a series of MON:CV dye solutions was kept at (5ml) (0:5, 0.5:4.5, 1:4, 1.5:3.5, 2:3, ..... 5:0).

#### **Application of the proposed methods**

Ten tablets (2.465gm, 1.859gm and respectively, 2.040gm) from each preparation, were grinded into fine powder. An precisely weighed amount of powder was transferred into a beaker and then were shaken with 50 ml of solvent (ethanol) and filtered. The filtrates and the washings were collected in a 100ml volumetric flask. and diluted up to the mark with solvent to obtain final concentration of 1000 µg/mL. The suggested method was successfully applied for the determination of MON in various commercial tablets; the results are shown in Table (4).

## **Results and Discussion**

Absorption spectrum of blue color product of MON against the blank at room



Fig. (2):- Absorption spectrum of "color product of MON" system against blank



Fig. (3):- Absorption spectrum of the blank against distilled water

## **Optimum conditions**

#### Effect of oxidation agent volume

Different and increasing volumes of oxidizing agent mixture (KBr: KBrO<sub>3</sub>) were added to Know their effect on the absorption

of the resulting product, It is clear from Fig. (4) that the best volume of the oxidizing agent is 0.75 ml which was used in subsequent studies.

temperature  $(25^{\circ}C)$  at 592nm is shown in (Fig. 2), and the blank against distilled water is shown in (Fig. 3).



Fig. (4):- Effect of oxidizing agent volume (KBr: KBrO<sub>3</sub>) on absorption of the (MON) product

#### Effect of the use of different acids

The acids used were ( $H_2SO_4$ , HCl,  $HNO_3$ ,  $CH_3COOH$ ), with a concentration of 1.0 M for each, and same volume of 0.5 ml for each, Table (1) shows that the best acid used to form the product is hydrochloric acid.

Table (1):- Effect of different types of acids on absorption values of the product

The acid used	Product absorption values		
HCl	0.845		
$H_2SO_4$	0.595		
HNO <sub>3</sub>	0.478		
CH <sub>3</sub> COOH	0.0		

#### Effect of the acid amount

Different volumes (0.2-2)ml of 0.1 M HCl were used, As shown in Fig. (5), the optimal added acid volume is 0.5 ml, after which,

the color of the formed product disappears gradually.



#### Fig. (5):- Effect of HCl on the absorption values of the product

#### Effect of the dye amount

Fig. (6) shows the effect of adding different volumes (0.5-3) ml of the CV dye on the

absorption of the product. The best added volume was 1.0 ml.



Fig. (6):- Effect of CV dye volumes on product absorption values

#### Effect of time on product stability

The effect of time was followed using optimum conditions every ten minutes for three hours, the product absorption was then taken the next day. Table (2) shows the stability of the absorption values at  $\lambda$ max.

with time, the absorption value of the product is fixed for 24 hours.

Time (min.)	Absorbance
5.0	0.792
10	0.845
20	0.844
30	0.845
40	0.843
50	0.843
60	0.844
120	0.845
180	0.844
24 hours	0.840

Table (2):- Effect of time on Stability of product

#### **Effect of Interferences**

The effect of interferences on the composition of the product was studied, and

not observed any effect, as shown in the table (3).

Interference	Added con. μg/mL	% RE	Added con. μg/mL	% RE
Lactose	50	-1.657	100	-2.13
Manitol	50	-3.787	100	-4.497
Sodium benzoate	50	-0.71	100	-1.657

 Table (3):- Effect of interferences

## The stoichiometry of the product

Under the optimum conditions, the stoichiometry of the reaction between MON and the dye was studied by mole–ratio and

continuous variation methods. The equivalence between dye and this drug was 1:1 (Figs. 7, 8).



Fig.(7):- Mole-ratio method of MON product



Fig.(8):- Continuous variation method of MON product

#### **Calibration curve**

Fig.(9) shows the linearity of the calibration curve obtained at optimal conditions, where the linearity was within concentrations (5-

50)  $\mu$ g/ml, which is equal to the volumes within (0.1-1.0) ml.



#### **Characteristics of calibration curve**

Calibration curve was constructed according to the optimum conditions in table (4).

Parameter	Value
$\lambda_{\max}.(nm)$	592
Beer's law (µg/ml)	5-50
Molar absorptivity(L/mol.cm)	$1.5691 \times 10^4$
Correlation coefficient (r)	0.9993
Limit of Detection (µg/ml)	0.209
Slope	0.0258
Intercept	0.1828
%RSD	0.174

Table (4):- characteristics of the calibration curve for	r
spectrophotometric determination of MON	

#### Application of the proposed methods

The results of determination of MON in the pharmaceutical preparations are shown in table (5).

pharmaceutical preparations	Content(mg) declared	Found(mg) by proposed method	%RE	%Recovery
Montix (Pioneer)	10	10.04	0.4	100.4
	10	9.93	-0.7	99.3
	10	10.12	1.2	101.2
Lukast (Pharma International)	10	9.99	-0.1	99.9
	10	9.82	-1.8	98.2
	10	10.23	2.3	102.3
Singular	10	10.22	2.2	102.2
	10	10.02	0.2	100.2
	10	9.69	-3.1	96.9

#### Table (4): Determination of MON in commercial tablets by the proposed spectrophotometric method

#### The suggested ractions

The proposed reaction can be based on how the MON drug is oxidized, by connection three groups of bromine to the ring

connected by the halogen group <sup>[20]</sup>, and how to convert the CV dye to Leuco form<sup>[21]</sup> as follows:

 $BrO_3 + 5Br + 6H^+ \longrightarrow 3Br_2 + 3H_2O$ 



Leuco form

# Conclusion

This method described here is simple, rapid, convenient and do not requires special working conditions unlike many other reported methods. The procedure showed shorter reaction time, stable colored species with inexpensive reagent. The determination can be performed at room temperature and do not require heating step. The proposed method can be applied for the determination of MON in pharmaceutical preparations (Tablet).

## References

- Lipkowitz, A. Myron and Navarra, Tova (2001) The Encyclopedia of Allergies (2nd ed.) Facts on File, New Y
- 2. ork, p. 178.
- "Asthma / Allergy " Archived 2012-06-14 at the Wayback Machine.. Mascothealth.com. Retrieved 9 April 2011.
- 4. Medline Plus, "Montelukast Na", American Society of Health-System Pharmacists, Inc. Disclaimer, U.S. National Library of Medicine, 2018.
- 5. MERCK & CO., INC., Whitehouse Station, NJ 08889, USA, Singular "Montelukast Sodium", 2009.
- N. Kanakadurga devi, A. Prameela rani, B. R. Madhavi, B. S. Mrudula, "New RP- HPLC method for the analyses of Montelukast Sodium in pharmaceutical dosage forms", International Journal of ChemTech Research, 2010, Vol. 2(1), pp. 471-475.
- K. Naga Raju, T. Gopala Swamy and A. Lakshmana Rao, "Development and v OF RP-HPLC validation method for the determination of Montelukast Sodium in bulk and in pharmaceutical formulation", ternational in Journal of Pharmaceutical, Chemical and

Biological Sciences, 2011, 1(1), pp. 12-16.

- 8. Bonthu Mohan Gandhi. Atmakuri Lakshmana Rao. Jangala "Method Rao. Venkateswara development validation for and simultaneous estimation of Montelukast Sodium and Desloratadine RP-HPLC". by American Journal of Analytical Chemistry, 2015, Vol. 6, pp. 651-658.
- 9. Smita Sharmaa, M. C. Sharma, D. V. Kohlib, A. D. Sharmac, "Development and validation of TLC-Densitometry method for simultaneous quantification of Sodium Montelukast and Levocetirizine Dihydrochloride pharmaceutical solid dosage form", Research Library Der Scholars Pharmacia Lettre, 2010, Vol. 2(1) pp. 489-494.
- 10. Suparna Tandulwadkar, J. Snehal More, S. Atul Rathore, R. Kakasaheb Mahadik, "Method development and the simultaneous validation for determination Fexofenadine of Hydrochloride and Montelukast Sodium in drug formulation using **High-Performance** normal phase Thin-Layer chromatography", Scholarly Research International Network, Volume 2012, pp. 1-7.
- 11. Kishore Konam. Pottabathula HariPrasad, Punuri Samuel Lukaraju, Sirajudeen, Md. Fareedullah M. A. and Md. Imtiaz Ahmed, "Determination of Montelukast Sodium and Levocetrizine Hydrochloride by using HPTLC method", Elixir Pharmacy, 2011, Vol. 38, pp. 4276-4278.
- 12. Hitesh. Vekaria, K. S. Muralikrishna and Mandip Sorathiya, "Development and validation of

HPTLC method for simultaneous estimation of montelukast sodium and Fexofenadine Hydrochloride in combined dosage form", Scholars Research Library Der Pharmacia Lettre, 2012, Vol. 4(3), pp. 755-762.

- 13. Saeed Haghighia, Mahmoud Reza Shapouria, Mitra Amoli-Divab, Kamyar Pourghazia and Hossein Afruzia, "HPTLC-Densitometric determination of Cetirizine and Montelukast analysis in combined tablet dosage forms", Iranian Journal of Pharmaceutical Research, 2013, Vol. 12(2), pp. 303-309.
- 14. Gulcemal Yildiz, Zeynep Aydogmuş, Jean-Michel Kauffmann, "Differential pulse Voltammetric determination of Montelukast in tablets and human plasma by using Chitosan Modified Carbon Paste Electrode", Electroanalysis An International Journal Devoted to Electroanalysis, Sensors and Bioelectronic Devices, 2013, Vol. 25(7), pp. 1569-1802.
- 15. Bernu Colkesen, Funda Ozturk and E. Pinar Erdenb," Electroanalytical characterization of Montelukast Sodium and its Voltammetric determination in pharmaceutical dosage form and biological fluids", J. Braz. Chem. Soc., 2016, Vol. 27(5), pp. 849-856.
- 16. Lovleen Kumar Garg, B. Ravi Kumar, Dr. Shakil S Sait, Dr. T. Krishnamurthy, "Determination of Montelukast Sodium in oral granules dosage forms by a simple and accurate UV spectrophotometric methods", International Journal of Pharmaceutical Sciences Review and Research, 2011, Vol. 7(2), pp. 69-72.
- 17. Nitin Kumar Patel, Pradeep Chouhan, Suresh Kumar Paswan and

Prakash Kumar Son, "Development and validation of UV а spectrophotometric method for simultaneous estimation of combination of Montelukast sodium Levocetirizine presence of in Dihydrochloride", Scholars Research Library Der Pharmacia Lettre, 2014, 6(3), pp. 313-321.

- 18. J. V. Shanmukha Kumar, P. Geeta Swarupa, S. V. M. Vardhan and D. Ramachandran, "Spectrophotometric determination of Montelukast Sodium in bulk and pharmaceutical formulations", Scholars Research Library Der Pharma Chemica, 2012, Vol. 4(2), pp. 720-724.
- K. Sayanna1, G. Venkateshwarlu, "Spectrophotometric determination of drugs and pharmaceuticals by Cerium (IV) Amaranth Dye Couple", IOSR Journal of Applied Chemistry, 2013, Vol. 5(4), pp. 1-9.
- 20. Raval Kashyap and Kevin Makavana- "Development of new colorimetric method and validation for determination of Loperamide in bulk and marketed formulation", IJPCBS, 2013, Vol. 3(2), pp. 215-226.
- 21. B. Karakapora Ch. Umakanthappa and N. Paregowda - "Titrimetric and modified spectrophotometric methods for the determination of Amlodipine Besylate using Bromate-Bromide mixture and two dyes" -Science Asia, 2006, Vol. 32, pp. 271-278.
- 22. U. Kanchan A. Anupama and K. T. Raunak - "Leuco Crystal Violet method for the determination of Nicorandil in bulk dosage" - Karbala International Journal of Modern Science, 2016, Vol. 2(1), pp. 1-9.